Physician profile
John Michael Schmidt
NPI 1467863076
$5,266.61
in general payments reported to CMS, 2019-2025
25 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 93% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.72 · 2020: $29.06 · 2021: $839 · 2022: $354 · 2023: $733 · 2024: $1,448 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.62 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,657.08 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Biotronik Nro, INC. | $841.67 | 2023-2025 | Prospera, Biotronik |
| Collegium Pharmaceutical, INC. | $473.18 | 2019-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $441.22 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Scilex Pharmaceuticals INC. | $372.17 | 2021-2025 | Ztlido |
| Globus Medical, INC. | $359.85 | 2025 | Senza |
| Abbott Laboratories | $215.73 | 2023-2025 | Eterna, Proclaim |
| Averitas Pharma INC. | $151.68 | 2024-2025 | Qutenza |
| Nevro Corp. | $147.51 | 2020-2024 | Senza |
| Forte Bio-Pharma LLC | $136.22 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Radius Health, INC. | $54.93 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $51.68 | 2021 | |
| Ibsa Pharma INC. | $51.45 | 2022-2023 | Tirosint, Licart |
| Vertex Pharmaceuticals Incorporated | $49.21 | 2024-2025 | |
| Si-Bone, INC. | $36.05 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $33.86 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $33.74 | 2023 | Horizant |
| Avanos Medical | $32.47 | 2021 | |
| Daiichi Sankyo INC. | $27.31 | 2025 | |
| Hikma Pharmaceuticals USA | $21.00 | 2024 | Kloxxado |
| Horizon Therapeutics Plc | $18.37 | 2021 | |
| Medtronic USA, INC. | $18.09 | 2020 | |
| Virtus Pharmaceuticals LLC | $17.06 | 2025 | Levorphanol Tartrate |
| Depuy Synthes Sales INC. | $14.32 | 2021 | |
| Stimwave Technologies Incorporated | $10.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.